Notably, TNFSF9 (CD137L) is a key activating immune checkpoint molecule, and its agonist, in combination with PD-L1, can potently activate and expand tumor-specific cytotoxic T cells, thereby enhancing their inhibitory and lethal effects on tumors (24). Here, CD274 is linked to neoplasm.